Enhancement of S(+)-zaltoprofen oral bioavailability using nanostructured lipid carrier system

Arch Pharm Res. 2022 Nov;45(11):822-835. doi: 10.1007/s12272-022-01413-2. Epub 2022 Oct 28.

Abstract

Zaltoprofen is a nonsteroidal anti-inflammatory drug with poor oral bioavailability. S(+)-zaltoprofen (SZPF)-loaded nanostructured lipid carriers (NLCs) were prepared to enhance oral bioavailability. SZPF-loaded NLCs (NLC-SZPF) were prepared using the hot-melting homogenization method and optimized using the Box-Behnken design. The characterization of optimized NLC-SZPF, in vitro release, cytotoxicity, cellular uptake, ex vivo permeability, and pharmacokinetic parameters were evaluated to confirm the advantages of NLC formulation. NLC-SZPF with a diameter of 105.5 ± 1.2 nm had a high encapsulation efficiency of 99.84 ± 0.01%. NLC-SZPF showed a sustained-release profile, high biocompatibility, and high permeability across the intestinal tract. The relative bioavailability of NLC-SZPF was 431.3% compared with that of SZPF after oral administration to experimental rats. NLC-SZPF was successfully optimized using experimental designs to enhance the oral bioavailability of SZPF. Hence, NLC-SZPF could be a promising approach to overcome the poor oral bioavailability of SZPF.

Keywords: Bioavailability; Box–Behnken design; Nanostructured lipid carrier; Optimization; S(+)-zaltoprofen.

MeSH terms

  • Administration, Oral
  • Animals
  • Biological Availability
  • Drug Carriers*
  • Excipients
  • Lipids
  • Nanostructures*
  • Particle Size
  • Rats
  • Solubility

Substances

  • Drug Carriers
  • pyranoprofen
  • Lipids
  • Excipients